Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) reported on Wednesday the availability of Atomoxetine Capsules, USP in the US market.
In addition, the company's Atomoxetine Capsules, USP is available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg with 30 counts bottle size. Atomoxetine is used to treat attention-deficit hyperactivity disorder (ADHD), including psychological, social, and other treatments. It may help to increase the ability to pay attention, concentrate, stay focused and stop fidgeting.
The company said the US Food and Drug Administration (USFDA) approved Atomoxetine Capsules, USP, is the therapeutic equivalent generic version of Strattera (atomoxetine) Capsules. Straterra is a registered trademark of Eli Lilly and Company.
For the most recent 12 months ending in August 2018, the Strattera brand and generic had US sales of about USD304m MAT, according to IMS Health.
Teva Launches a Generic Version of Tracleer Tablets in the United States
Rising Pharmaceuticals Launches Mesalamine Suppository
Lannett Company commences marketing Aspirin and Extended-Release Dipyridamole Capsules
Teva Launches Generic Version of Ranexa Extended-Release Tablets in the United States
Perrigo wins US FDA final approval for AB rated generic Voltaren Gel 1%
Teva Launches of a Generic Version of Delzicol Delayed-Release Capsules in the United States
Teva Announces Launch of a Generic Version of Tarceva Tablets in the United States
Amerigen wins US FDA approval for generic Penicillamine in 250 mg capsules
Amerigen Pharmaceuticals Limited wins US FDA approval for Penicillamine Capsules USP in 250 mg
Dr. Reddy's Laboratories Launches Testosterone Gel, 1.62% in the US Market